Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds
Xenon Pharmaceuticals (XENE) has attracted attention after recent share price moves, with the stock closing at $68.92. Investors are weighing its performance over the past month and past 3 months, alongside longer term returns.
See our latest analysis for Xenon Pharmaceuticals.
The recent 1 day share price decline of 2.87% comes after a strong run, with a 30 day share price return of 32.28% and a year to date share price return of 54.91%. The 1 year total shareholder return of 111.41% points to powerful momentum over a longer stretch.
If Xenon Pharmaceuticals has you watching the biotech space more closely, this could be a good moment to broaden your search with our screener of 40 healthcare AI stocks
Bulls point to Xenon Pharmaceuticals’ recent gains and late stage epilepsy program, while bears focus on ongoing losses and the risks around clinical trials and zero revenue. Which side do current valuation metrics lean toward next?
Most Popular Narrative: 14.4% Undervalued
The most followed narrative currently pegs Xenon Pharmaceuticals’ fair value at $80.56, compared with the recent close at $68.92. This puts a spotlight on what is built into those assumptions.
Advancing azetukalner toward multiple late stage readouts in focal onset and generalized seizures positions Xenon to tap a growing pool of refractory epilepsy patients who need better tolerated, easy to use therapies. This supports a step change in revenue on approval and later expands earnings as fixed R&D is leveraged.
Want to see what backs that projected revenue jump? The narrative leans on aggressive growth, rising margins, and a future earnings multiple that is anything but conservative.
Result: Fair Value of $80.56 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the bullish Xenon Pharmaceuticals story leans heavily on clean late stage azetukalner data and supportive reimbursement, and setbacks on either front could quickly challenge that 14.4% undervaluation narrative.
Find out about the key risks to this Xenon Pharmaceuticals narrative.
Another View: Xenon Pharmaceuticals Through a P/B Lens
So far, Xenon Pharmaceuticals looks attractive on fair value models, with the stock trading at 82.5% below an estimate of future cash flow value. Yet on a simple P/B basis, XENE sits at about 5x, richer than the US Biotechs industry average of 2.7x, even if still below the 7.9x peer average. This raises a question: does paying a higher multiple than the wider industry, while relying on bullish long term cash flow assumptions, leave more upside or more valuation risk?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment split between the risks and rewards of Xenon Pharmaceuticals, this is a good time to assess the data yourself and move decisively. Start by weighing the 2 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Xenon Pharmaceuticals?
If Xenon Pharmaceuticals has sharpened your focus, do not stop here. Use these screeners to quickly spot fresh opportunities that fit different investing goals.
- Zero in on potential bargains by scanning companies that combine quality fundamentals with attractive prices using the 45 high quality undervalued stocks.
- Strengthen your income game by reviewing companies known for resilient payouts with the 9 dividend fortresses.
- Shift your attention to resilience first and assess stocks with lower overall risk profiles through the 79 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com